To read the full story, subscribe or sign in.

Flamel Finds New Basulin Partner, Signs $165M Bristol-Myers Deal

Aug. 28, 2003

Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Feb. 26, 2025.

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 26, 2025

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...